Pfizer Inc. (PFE)

NYSE - NYSE Delayed Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

37.08-0.41 (-1.09%)

At close: 4:02PM EDT

37.15 +0.07 (0.19%)
Before hours: 5:27AM EDT

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Price Crosses Moving Average

View all chart patterns

Performance Outlook

Previous Close	37.49
Open	37.35
Bid	0.00 x 3000
Ask	0.00 x 2200
Day's Range	37.06 - 37.45
52 Week Range	27.88 - 40.97
Volume	16,249,516
Avg. Volume	24,732,906

Market Cap	206.049B
Beta (5Y Monthly)	0.66
PE Ratio (TTM)	14.68
EPS (TTM)	2.53
Earnings Date	Oct 27, 2020
Forward Dividend & Yield	1.52 (4.05%)
Ex-Dividend Date	Nov 05, 2020
1y Target Est	41.33

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

-17% Est. Return

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

Editor's Pick
Yahoo Finance Video
Coronavirus Latest: Wednesday, October 21
As new cases in the United States average at around 59,000 a day with the most recent surge, AstraZeneca is reportedly going to re-start its vaccine trials in the U.S. according to Reuters and Eli Lilly is bringing in an outside advisor to oversee the issues with its New Jersey plant. Yahoo Finance’s Anjalee Khemlani joins The Final Round to discuss the latest on the coronavirus.
- Volunteers are deliberately contracting COVID-19 for vaccine research
  Entercom Communications
- AstraZeneca COVID-19 vaccine trial continues despite Brazilian volunteer death
  Yahoo News Video
Investor's Business Daily
U.S. Health Officials Optimistic One Or Two Covid-19 Vaccines Ready This Year
The leaders of key U.S. health agencies said in a media briefing Wednesday they are optimistic one or two Covid-19 vaccines will be approved and begin distribution later this year.
- Global Dendritic Cell Cancer Vaccine Immunotherapy Provenge Therapy Market & Clinical Trials Report 2026
  GlobeNewswire
- Coronavirus vaccine: Infectious disease doctor who got the jab reveals her experience
  The Independent
Reuters
U.S. likely to have enough COVID-19 vaccines for all vulnerable Americans by year end -official
The United States is likely to have enough safe and effective COVID-19 vaccines available to inoculate the most vulnerable Americans by the end of 2020, Health and Human Services Secretary Alex Azar said on Wednesday. The U.S. government is "cautiously optimistic" that one or two vaccines, likely from Pfizer Inc or Moderna Inc , will be available by the end of the year and can begin to be distributed to Americans, officials said during a news conference. Azar said he expects all seniors, healthcare workers, and first responders will be able to receive a vaccine as soon as January, with the rest of the American public able to get a vaccine by April.